Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter, Randomized, Double-blind, Placebo-controlled Phase 3 Trial to Evaluate the Efficacy and Safety of Elagolix Tablets in Patients With Moderate or Severe Endometriosis-associated Pain

NCT06076486 is registered in ClinicalTrials.gov with Nanjing Chia-tai Tianqing Pharmaceutical as lead sponsor.

NCT NCT06076486
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06076486 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter, Randomized, Double-blind, Placebo-controlled Phase 3 Trial to Evaluate the Efficacy and Safety of Elagolix Tablets in Patients With Moderate or Severe Endometriosis-associated Pain
Lead sponsor
Nanjing Chia-tai Tianqing Pharmaceutical
Phase
Phase 3
Overall status
Completed
Start date
September 14, 2023
Completion date
April 2, 2025
Enrollment
202 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

endometriosis